Phillips-Medisize Adds Dr. Robert Langer to Strategic Advisory Board
Hudson,WI and Cambridge, MA – February 7, 2017 - Phillips-Medisize Corporation announced today the addition of Dr. Robert Langer to the Phillips-Medisize Advisory Board. The Board works closely with the executive team to guide and counsel the company on its continued growth strategy and future opportunities.
Dr. Robert Langer is the David H. Koch Institute Professor at MIT, one of 13 Institute Professors at MIT. His patents (1,130 and counting) have been licensed or sublicensed to over 300 pharmaceutical, chemical, biotechnology and medical device companies. Dr. Langer has written nearly 1,380 articles and is the most cited engineer in history. He served as a member of the US FDA’s SCIENCE Board, the agency’s highest advisory board from 1995 to 2002, serving as Chairman for four years.
Dr. Langer has received over 220 major awards, and is one of four living individuals to have received both the United States National Medal of Science and the United States Medal of Technology. In 1989 Dr. Langer was elected to the National Academy of Medicine, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences, and in 2012 he was elected to the National Academy of Inventors.
His research is a combination of medicine, materials science and chemical engineering. The Langer Lab at MIT focuses on the interface of biotechnology and materials science, with a major focus on the study and development of polymers to manage the controlled release of drugs, over extended periods of time.
As a member of the Advisory Board, Dr. Langer will advise on drug delivery technology unmet needs and evolving trends, biotechnology and material science technical issues related to drug delivery devices, and specific complex scientific and technical issues important to FDA and international regulatory bodies. Further, he will provide guidance on training programs that develop the human capital base at Phillips-Medisize from a technical capability perspective.
“Phillips-Medisize is a terrific company and has done a great job, particularly in the area of manufacturing novel biomedical devices. I'm delighted to be working with them,” commented Dr.
“Dr. Langer’s significant research accomplishments will be a valuable addition to our Advisory Board, complementing the commercial backgrounds of our other Board members, which include leadership positions at Roche, Becton-Dickinson, and Philips Healthcare, among others,” commented Matt Jennings, Chairman, CEO and President, Phillips-Medisize. “Our global team of 4,300 employees will benefit from Dr. Langer’s guidance and counsel on the wide range of innovation, design, and development programs we are pursuing on behalf of our biopharmaceutical customers.”
For more information, contact:
Phone +1 715 748 8928
Paula Kasper (Europe)